The National Institutes of Health is offering a grant opportunity titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)". This grant aims to support studies that investigate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. The studies can be conducted using animal, cell culture, and/or human tissue models. The proposed models or experimental readouts should incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. The grant provides funding for mechanistic studies that address various aspects, including the impact of COVID-19 on CNS pathology and cognitive outcomes in the presence of AD/ADRD pathology, the acceleration of AD/ADRD pathology and cognitive deficits by COVID-19 in prodromal models, and the predisposition of COVID-19 for AD/ADRD and its interaction with comorbid conditions and risk factors. The grant does not require cost sharing or matching and is open to various eligible applicants. The deadline for application submission is October 4, 2024. For more information and to apply, visit the following link: Neuropathological Interactions Between COVID-19 and ADRD Grant.